# A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

> **NCT03641560** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 52 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Androgen deprivation therapy (ADT)

## Key facts

- **NCT ID:** NCT03641560
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-19
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-02-20
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03641560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03641560, "A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03641560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*